글로벌 Peer 불러오는 중…
산업별 글로벌 동종업체의 매출·수익성·밸류에이션을 USD 기준으로 비교
한국 기업의 위치는 글로벌 안에서 봐야 보입니다. 동일 산업의 글로벌 리더들과 매출 규모·수익성·밸류에이션을 나란히 놓고 비교합니다.
| 기업 | 국가 | 매출 | 영업이익률 | 순이익률 | ROE | PER | PBR | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|
| McKesson (의약유통)5_유통/판매 | US | $403.4B | 1.5% | 1.2% | -571.0% | — | — | — |
| Cencora (의약유통)5_유통/판매 | US | $321.3B | 0.8% | 0.5% | 89.0% |
| — |
| — |
| — |
| Cardinal Health (유통)5_유통/판매 | US | $222.6B | 1.0% | 0.7% | -56.4% | — | — | — |
| Novo Nordisk (비만/당뇨)4_완제의약품 | DK | $101.4B | 18.5% | 14.0% | 52.8% | — | — | — |
| Johnson & Johnson (제약/의료기기)4_완제의약품 | US | $94.2B | 27.2% | 28.5% | 32.9% | — | — | — |
| AstraZeneca (항암/백신)4_완제의약품 | GB | $72.8B | 23.4% | 17.4% | 21.0% | — | — | — |
| Eli Lilly (비만/당뇨)4_완제의약품 | US | $65.2B | 45.6% | 31.7% | 77.8% | — | — | — |
| Merck (항암/백신)4_완제의약품 | US | $65.0B | 34.5% | 28.1% | 34.7% | — | — | — |
| Pfizer (백신/항암)4_완제의약품 | US | $62.6B | 16.3% | 12.4% | 9.0% | — | — | — |
| AbbVie (면역/종양)4_완제의약품 | US | $61.2B | 24.6% | 6.9% | -129.2% | — | — | — |
| BMS (항암/면역)4_완제의약품 | US | $47.2B | 23.8% | 14.9% | 38.1% | — | — | — |
| Sanofi (백신/면역)4_완제의약품 | FR | $45.4B | 15.6% | 17.9% | 10.9% | — | — | — |
| Thermo Fisher (분석/CDMO)3_원료의약품 | US | $44.6B | 17.4% | 15.1% | 12.5% | — | — | — |
| Abbott Labs (진단/기기)6_지원서비스 | US | $44.3B | 18.2% | 14.7% | 12.5% | — | — | — |
| GSK (백신/호흡기)4_완제의약품 | GB | $40.5B | 24.8% | 19.3% | 38.4% | — | — | — |
| Amgen (바이오의약)1_연구개발 | US | $36.8B | 24.7% | 21.0% | 89.1% | — | — | — |
| Medtronic (의료기기)6_지원서비스 | US | $36.4B | 18.8% | 13.2% | 9.7% | — | — | — |
| Gilead Sciences (항바이러스)1_연구개발 | US | $29.4B | 39.7% | 28.9% | 37.6% | — | — | — |
| Stryker (정형외과)6_지원서비스 | US | $25.1B | 19.5% | 12.9% | 14.5% | — | — | — |
| Danaher (생명과학장비)6_지원서비스 | US | $24.6B | 19.1% | 14.7% | 6.8% | — | — | — |
| Boston Scientific (심혈관)6_지원서비스 | US | $20.1B | 18.6% | 14.4% | 11.8% | — | — | — |
| IQVIA (임상시험대행)2_임상개발 | US | $16.3B | 14.2% | 8.3% | 20.9% | — | — | — |
| Regeneron (항체치료)1_연구개발 | US | $14.3B | 25.8% | 31.4% | 14.4% | — | — | — |
| Vertex Pharma (유전자치료)1_연구개발 | US | $12.0B | 38.0% | 33.0% | 21.2% | — | — | — |
| Intuitive Surgical (수술로봇)6_지원서비스 | US | $10.1B | 29.3% | 28.4% | 16.0% | — | — | — |
| Biogen (바이오텍)1_연구개발 | US | $9.9B | 18.4% | 13.1% | 7.1% | — | — | — |
| Edwards Lifesciences (심장판막)6_지원서비스 | US | $6.1B | 20.8% | 17.7% | 10.4% | — | — | — |
| Lonza (의약품위탁생산)3_원료의약품 | CH | $5.9B | 19.0% | 13.9% | 11.5% | — | — | — |
| Dexcom (진단)6_지원서비스 | US | $4.7B | 19.6% | 17.9% | 30.5% | — | — | — |
| Charles River (전임상)2_임상개발 | US | $4.0B | 10.0% | -3.6% | -4.6% | — | — | — |
| Moderna (mRNA백신)1_연구개발 | US | $3.3B | -93.0% | -85.4% | -32.6% | — | — | — |
| West Pharma (포장)3_원료의약품 | US | $3.1B | 20.7% | 16.1% | 15.5% | — | — | — |
| Medpace (임상시험대행)2_임상개발 | US | $2.5B | 21.1% | 17.8% | 98.3% | — | — | — |